Nom du produit:7-Methoxy-1,1-dimethyl-3,4-dihydronaphthalen-2(1H)-one
IUPAC Name:7-methoxy-1,1-dimethyl-1,2,3,4-tetrahydronaphthalen-2-one
- CAS：1865-83-4
- Formule moléculaire：C13H16O2
- Pureté：95%
- Numéro de catalogue：CM140627
- Poids moléculaire：204.27
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:1865-83-4
- Formule moléculaire:C13H16O2
- Point de fusion:-
- Code SMILES:O=C1C(C)(C)C2=C(C=CC(OC)=C2)CC1
- Densité:
- Numéro de catalogue:CM140627
- Poids moléculaire:204.27
- Point d'ébullition:
- N° Mdl:MFCD20274514
- Stockage:
Category Infos
- Naphthalenes
- Naphthalene is a hydrocarbon produced by the distillation of coal tar and is an aromatic white crystalline substance. Naphthalene is the most abundant component in coal tar. It is used as an insect repellant and insect fumigant. The compound is used in the manufacture of celluloid, dyes, hydrogenated naphthalenes, oil fumes, smokeless powders and synthetic resins.
Column Infos
- Alectinib
- Genentech, a member of the Roche Group, has announced that its ALK inhibitor Alecensa® (Alectinib) met its primary endpoint of disease-free survival (DFS) at a scheduled interim analysis of the phase 3 ALINA trial. Alecensa as adjuvant therapy resulted in statistically significant DFS and clinically meaningful improvement.
Worldwide, lung cancer is one of the most common cancers, with NSCLC accounting for 80% to 85% of all lung cancer cases. Despite adjuvant chemotherapy, about half of patients with early-stage lung cancer experience cancer recurrence after surgery. Recent therapeutic innovations, including immunotherapy, have improved the outlook for some patients with early-stage NSCLC; however, there are currently no ALK inhibitors approved for early-stage ALK-positive disease. Alecensa is the first ALK inhibitor proven in a Phase 3 trial to reduce the risk of disease recurrence or death in patients with early-stage ALK-positive NSCLC.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Recherche 
+86 21 5895 0110 
